BC Innovations | Feb 2, 2018
Translation in Brief

Untangling MS

Multiple sclerosis researchers have typically sought to dial down inflammation and reduce disease metrics that encompass a wide range of disabilities. A UCLA team is bucking those trends by identifying disease-modifying targets in specific brain...
BC Innovations | Feb 1, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest agonizing ABCA1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a tool compound ABCA1 agonist increased walking ability and...
BC Innovations | May 31, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Mouse intestinal organoids could be used to model intestinal drug metabolism and toxicity. The organoids were generated by treating primary mouse crypt cells isolated from the small intestine with a cocktail of...
BioCentury | Dec 31, 2016

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Jul 27, 2015
Clinical News

MDCO-216: Phase I data

A double-blind, placebo-controlled Phase I trial in 24 healthy volunteers and 24 patients with coronary artery disease (CAD) showed that single doses of 5-40 mg/kg IV MDCO-216 were well tolerated with no serious events or...
BC Extra | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
BC Week In Review | Sep 15, 2014
Clinical News

Cerenis HDL regulatory update

Cerenis said the European Commission granted Orphan Drug designation to CER-001 to treat apolipoprotein A-1 (APOA1) and ATP-binding cassette transporter 1 ( ABCA1 ) deficiencies. The company said inherited defects in the APOA1 or ABCA1 gene can...
BC Innovations | Oct 10, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Hypercholesterolemia; hyperlipidemia ATP-binding cassette sub-family A member 1 (ABCA1); microsomal triglyceride transfer protein (MTTP; MTP) Mouse studies suggest inhibiting MTP and ABCA1 in the...
BC Innovations | Apr 18, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Age-related macular degeneration (AMD) ATP-binding cassette sub-family A member 1 (ABCA1); liver X receptor (LXR); microRNA-33 (miR-33) In vitro and mouse studies suggest increasing...
BioCentury | Sep 12, 2011
Product Development

Reviving CETP

Evidence is accumulating that the next generation of CETP inhibitors may be able to avoid the off-target effects that doomed Pfizer Inc. 's torcetrapib. Roche reported Phase IIb data in late August showing its dalcetrapib...
Items per page:
1 - 10 of 21